Dr. Mark W.I. Webster

In a recent study we used the AutoGenomics 2C19 test to rapidly screen for polymorphisms associated with a reduced response to the drug" said Dr. Mark Webster, Director of Cardiac Catheterization at the Auckland City Hospital.
...
"We are pleased that Dr. Webster and Dr. Gladding have taken a pioneering role in assessing the role of genetic variants in Clopidogrel dosing to ensure patient safety.

with non-STEMI acute coronary syndromes," said Mark W.I. Webster, MD, director of the cardiac catheterization laboratory at Auckland City Hospital, Auckland, New Zealand.
...
For the study, Dr. Webster and his colleagues recruited 151
...
patients," Dr. Webster said."However, there are some patients who have major complications from distal embolism.We need better ways of identifying high-risk patients and lesions."

Dr. Webster will present the results of the "Angioplasty

Mark Webster, Auckland City Hospital, New Zealand

Dr. Webster presented data from the A-F trial [1], which looked at the use of coronary artery stenting over the FilterWire EZ system versus a conventional guidewire in patients with non-ST segment elevation myocardial infarction (NSTEMI).

Dr.Mark Webster of Auckland City Hospital, New Zealand, provided an elegant overview of catheter approaches of this clinical significant problem.

"PCI is associated with myonecrosis in about 25 percent of patients with non-STEMI acute coronary syndromes," said Mark W.I. Webster, MD, director of the cardiac catheterization laboratory at Auckland CityHospital, Auckland, New Zealand.
...
For the study, Dr. Webster and his colleagues recruited 151 patients treated at 14 medical centers in New Zealand, Australia and Canada, randomly assigning them to protection with the FilterWire or to conventional PCI without vascular protection.The researchers found that the rates of major cardiovascular complications during hospitalization -- consisting of death, heart attack, emergency bypass surgery, or repeat procedure in the treated artery -- were no different in the two groups (12 percent in the FilterWire group vs.10 percent in the control group).There were also no significant differences between the groups in the post-procedure release of enzymes that signal damage to the heart muscle.

"The device does not appear warranted for routine use in these patients," Dr. Webster said."However, there are some patients who have major complications from distal embolism.We need better ways of identifying high-risk patients and lesions."

Dr. Webster will present the results of the "Angioplasty Balloon-Associated Coronary Debris and the EZ FilterWire" (A-F) study on Sunday, March 30 at 8:00 a.m. CDT in the Grand Ballroom, S100.

"PCI is associated with myonecrosis in about 25 percent of patients with non-STEMI acute coronary syndromes," said Mark W.I. Webster, MD, director of the cardiac catheterization laboratory at Auckland City Hospital, Auckland, New Zealand.
...
For the study, Dr. Webster and his colleagues recruited 151 patients treated at 14 medical centers in New Zealand, Australia and Canada, randomly assigning them to protection with the FilterWire or to conventional PCI without vascular protection. The researchers found that the rates of major cardiovascular complications during hospitalization-consisting of death, heart attack, emergency bypass surgery, or repeat procedure in the treated artery-were no different in the two groups (12 percent in the FilterWire group vs. 10 percent in the control group). There were also no significant differences between the groups in the post-procedure release of enzymes that signal damage to the heart muscle.

"The device does not appear warranted for routine use in these patients," Dr. Webster said. "However, there are some patients who have major complications from distal embolism. We need better ways of identifying high-risk patients and lesions."

Dr. Webster will present the results of the "Angioplasty Balloon-Associated Coronary Debris and the EZ FilterWire" (A-F) study on Sunday, March 30 at 8:00 a.m. CDT in the Grand Ballroom, S100.

Mark Webster MD, Director, Cardiac Catheterization Laboratories, Green Lane Hospital, Auckland, New Zealand was among the first to test the system."We were pleased to participate in the initial trials of this promising new technology.We have used the Volcano thermography system in nine patients with coronary disease.In each case the device performed as expected."Dr. Webster will present his initial results during the scientific sessions at the 2002 Transcatheter Cardiovascular Therapeutic ("TCT") international symposium on Wednesday, September 25, 2002 at the Washington Convention Center, Washington DC.

"The Volcano Therapeutics catheter has a simple, but elegant design and was easily and safely deployed during several cardiac interventions.

Mark Webster MD, Director, Cardiac Catheterization Laboratories, Green Lane Hospital, Auckland, New Zealand was among the first to test the system."We were pleased to participate in the initial trials of this promising new technology.We have used the Volcano thermography system in nine patients with coronary disease.In each case the device performed as expected."Dr. Webster will present his initial results during the scientific sessions at the 2002 Transcatheter Cardiovascular Therapeutic ("TCT") international symposium on Wednesday, September 25, 2002 at the Washington Convention Center, Washington DC.

"The Volcano Therapeutics catheter has a simple, but elegant design and was easily and safely deployed during several cardiac interventions.

Mark Webster MD, Director, Cardiac Catheterization Laboratories, Green Lane Hospital, Auckland, New Zealand was among the first to test the system. "We were pleased to participate in the initial trials of this promising new technology. We have used the Volcano thermography system in nine patients with coronary disease. In each case the device performed as expected. Dr. Webster will present his initial results during the scientific sessions at the 2002 Transcatheter Cardiovascular Therapeutic ("TCT") international symposium on Wednesday, September 25, 2002 at the Washington Convention Center, Washington DC.